Non-Alcoholic Steatohepatitis (NASH) – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis – Drugs in Development, 2021, provides an overview of the Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline landscape.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 72, 63, 7, 190, 78 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 8 and 2 molecules, respectively.

Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (Gastrointestinal).

– The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Non-Alcoholic Steatohepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

180 Life Corp

89bio Inc

AbbVie Inc

ABIONYX Pharma SA

Abivax SA

Abliva AB

Acquist Theraputics, Inc.

AdAlta Ltd

Addpharma Inc

Afimmune Biopharma Ltd

Akero Therapeutics Inc

Albireo Pharma Inc

Aldeyra Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Non-Alcoholic Steatohepatitis (NASH) - Overview

Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development

Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment

Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics Development

Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles

Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects

Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products

Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Companies, 2021 (Contd..3)

Number of Products under Development by Companies, 2021 (Contd..4)

Number of Products under Development by Companies, 2021 (Contd..5)

Number of Products under Development by Companies, 2021 (Contd..6)

Number of Products under Development by Companies, 2021 (Contd..7)

Number of Products under Development by Companies, 2021 (Contd..8)

Number of Products under Development by Companies, 2021 (Contd..9)

Number of Products under Development by Companies, 2021 (Contd..10)

Number of Products under Development by Companies, 2021 (Contd..11)

Number of Products under Development by Companies, 2021 (Contd..12)

Number of Products under Development by Companies, 2021 (Contd..13)

Number of Products under Development by Companies, 2021 (Contd..14)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Companies, 2021 (Contd..5)

Products under Development by Companies, 2021 (Contd..6)

Products under Development by Companies, 2021 (Contd..7)

Products under Development by Companies, 2021 (Contd..8)

Products under Development by Companies, 2021 (Contd..9)

Products under Development by Companies, 2021 (Contd..10)

Products under Development by Companies, 2021 (Contd..11)

Products under Development by Companies, 2021 (Contd..12)

Products under Development by Companies, 2021 (Contd..13)

Products under Development by Companies, 2021 (Contd..14)

Products under Development by Companies, 2021 (Contd..15)

Products under Development by Companies, 2021 (Contd..16)

Products under Development by Companies, 2021 (Contd..17)

Products under Development by Companies, 2021 (Contd..18)

Products under Development by Companies, 2021 (Contd..19)

Products under Development by Companies, 2021 (Contd..20)

Products under Development by Companies, 2021 (Contd..21)

Products under Development by Companies, 2021 (Contd..22)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Target, 2021 (Contd..2)

Number of Products by Stage and Target, 2021 (Contd..3)

Number of Products by Stage and Target, 2021 (Contd..4)

Number of Products by Stage and Target, 2021 (Contd..5)

Number of Products by Stage and Target, 2021 (Contd..6)

Number of Products by Stage and Target, 2021 (Contd..7)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2021 (Contd..3)

Number of Products by Stage and Mechanism of Action, 2021 (Contd..4)

Number of Products by Stage and Mechanism of Action, 2021 (Contd..5)

Number of Products by Stage and Mechanism of Action, 2021 (Contd..6)

Number of Products by Stage and Mechanism of Action, 2021 (Contd..7)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by 180 Life Corp, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by 89bio Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by AbbVie Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ABIONYX Pharma SA, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Abivax SA, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Abliva AB, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Acquist Theraputics, Inc., 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by AdAlta Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Addpharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Afimmune Biopharma Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Akero Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Albireo Pharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Aldeyra Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Algernon Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Aligos Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Allysta Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Alnylam Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Altavant Sciences Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Altay Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Alteogen Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Altimmune Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Amgen Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Angion Biomedica Corp, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Anteris Bio, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by AptaBio Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by AptamiR Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Araim Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Arcturus Therapeutics Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Arkay Therapeutics LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Arrowhead Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ARTham Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Ascletis Pharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Asdera LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Ashvattha Therapeutics LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Assembly Biosciences Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by AstraZeneca Plc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Auransa Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Avaliv Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Avolynt Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Axcella Health Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Bast Biotechnology LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by BBN Cardio Therapeutics, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by BerGenBio ASA, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Betagenon AB, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Bioio LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Bird Rock Bio Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Blade Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by BLR Bio LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Boehringer Ingelheim International GmbH, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Boston Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Brexogen Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Bridge Biotherapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Bristol-Myers Squibb Co, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Buto Biopharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Cadila Healthcare Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Califia Bio Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Can-Fite BioPharma Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Carmot Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by CellCure, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Centaurus Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ChemoCentryx Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ChemomAb Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Chengdu Fanxi Biopharma Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by China NT Pharma Group Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ChunLab Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Circadian Therapeutics, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Cirius Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by CohBar Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Coherus BioSciences Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ConSynance Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Continuum Biosciences Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Corcept Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by CSPC Pharmaceutical Group Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Curacle Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Curadim Pharma Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Cyclerion Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Cyrus Therapeutics, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Cytodyn Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by D&D Pharmatech Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by DeckTherapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Dicerna Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Dr. Falk Pharma GmbH, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by DURECT Corp, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Eli Lilly and Co, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Enanta Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by EncuraGen Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Engitix Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Enveda Biosciences Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Enyo Pharma SA, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Enzychem Lifesciences Corp, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Epitracker Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Esperion Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Eternygen GmbH, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Fochon Pharmaceutical Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Forma Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Future Medicine Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Galectin Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Galecto Biotech ApS, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Galmed Pharmaceuticals Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by GAT Therapeutics SL, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by General Regeneratives Shanghai Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Genfit SA, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by GenKyoTex SA, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by GI Innovation Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Gilead Sciences Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Gmax Biopharm LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Guangdong East Sunshine Pharmaceutical Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by H. Lundbeck AS, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by HemoShear Therapeutics LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Hepagene Therapeutics Shanghai Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Hepanova Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by HepaRegeniX GmbH, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Hepion Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Heprotech Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by HighTide Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Hinova Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by HK inno.N Corp, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by HotSpot Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Ildong Pharmaceutical Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Imago Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ImmuneMed Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Immupharma Plc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Immuron Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Indalo Therapeutics Inc (Inactive), 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Inmune Bio Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Innovimmune Biotherapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Inorbit Therapeutics AB, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Integral Molecular Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Intercept Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by INVENT Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by InventisBio Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Inventiva, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Ionis Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by J2H Biotech, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Jecure Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Joyce Biotech Corp, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by KinDex Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Kinomedica Pty Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Kirrhos Pharmaceuticals LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by KoBioLabs Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Korea United Pharm Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Kowa Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Krisani Bio Sciences Pvt Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Kyorin Pharmaceutical Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Laekna Therapeutics Shanghai Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Landos Biopharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by LG Chem Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by LifeMax Laboratories Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Liminal BioSciences Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Lin Bioscience Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Lipidio Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Lipocine Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by LISCure Biosciences Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Macrophage Pharma Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Macrophage Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Madrigal Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Mallinckrodt Plc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Marvel Biotechnology Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Max Biopharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by MedPacto Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Melior Pharmaceuticals I Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Merck & Co Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Metabolic Solutions Development Company LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Metabolys SAS, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Metacrine Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by MetiMedi Pharmaceuticals Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Micelle BioPharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Mikrobiomik Healthcare Company SL, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Mina Therapeutics Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Mitotech SA, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Mitotherapeutix LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Mitsubishi Tanabe Pharma Corp, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Mperia Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Nanjing Sanhome Pharmaceutical Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Nanjing Transthera Biosciences Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Nano Intelligent Biomedical Engineering Corp, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by NeuroBo Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Nexel Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by NGM Biopharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Nippon Chemiphar Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Nivarta Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by NorthSea Therapeutics BV, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Novartis AG, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Novo Nordisk AS, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by NuSirt Biopharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Oasis Pharmaceuticals LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by OncoArendi Therapeutics SA, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Onegene Biotechnology Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Oramed Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Osteoneurogen Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Palo BioFarma SL, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Pattern Therapeutics, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by PegBio Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Pfizer Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by pH Pharma Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Pharmaxis Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Phenex Pharmaceuticals AG, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Pleiogenix, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Pliant Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Poxel SA, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Promethera Biosciences SA, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Proterris Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Protheragen Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by PTC Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by RadBio, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Redx Pharma Plc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Regenasome Pty Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Regulus Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Rejuvenation Technologies Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by reMYND NV, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Revive Therapeutics Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Rhamnopharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Ridgeline Therapeutics LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Rivus Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Sagimet Biosciences, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Saje Pharma LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Salix Pharmaceuticals Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ScandiCure AB, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Sciwind Biosciences Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Scohia Pharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Seal Rock Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Seres Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by SFA Therapeutics LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Shanghai Anruite Biological Medicine Technology Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Shaperon Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Shionogi & Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Sinew Pharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Sino Biopharmaceutical Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Sirnaomics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by SparkBioPharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Standigm Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by SteroTherapeutics LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Sveikatal Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Synlogic Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by T3D Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Terns Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by TES Pharma SRL, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Theratechnologies Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Thetis Pharmaceuticals LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Thoth Science Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by TiumBio Co Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Tiziana Life Sciences Plc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by TRACON Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by TreeFrog Therapeutics SAS, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Twoxar Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by UGISense AG, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Uni-Bio Science Group Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Unicyte AG, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Valin Technologies Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Vascular Biogenics Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Vectus Biosystems Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Venenum Biodesign LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Venn Therapeutics LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Verlyx Pharma Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Vidasym Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Viking Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Viscient Biosciences LLC, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Visionary Pharmaceuticals Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Vivazome Therapeutics Pty Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Vivoryon Therapeutics NV, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Vivus Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by vTv Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Wave Life Sciences Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Xenexus Pharmaceuticals Pty Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Xfibra Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by XORTX Therapeutics Inc, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Yuhan Corp, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Zebra Discovery Ltd, 2021

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Zhejiang Doer Biologics Corp, 2021

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, 2021

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, 2021 (Contd..1)

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, 2021 (Contd..2)

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, 2021 (Contd..3)

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, 2021 (Contd..4)

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, 2021 (Contd..5)

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, 2021 (Contd..6)

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, 2021 (Contd..7)

Non-Alcoholic Steatohepatitis (NASH) – Discontinued Products, 2021

Non-Alcoholic Steatohepatitis (NASH) – Discontinued Products, 2021 (Contd..1)

List of Figures

List of Figures

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports